Syntara (ASX:SNT), a clinical-stage drug development company, has announced the completion of patient recruitment for its Phase 2, randomised, double-blind, placebo-controlled trial of SNT-4728, a first-in-class neuro-targeted anti-inflammatory therapy, in individuals with isolated REM sleep behaviour disorder.
Affecting approximately 2% of people over 50, iRBD is a severe sleep disorder that is strongly linked to neurodegenerative disease, with up to 90% of patients eventually developing conditions such as Parkinson’s disease.
The multi-centre study is evaluating both the safety of SNT-4728 and its potential to reduce neuroinflammation in key brain regions implicated in disease progression, with exploratory endpoints assessing improvement in clinical symptoms.
Conducted in collaboration with leading academic centres and supported by Parkinson’s UK through its Parkinson’s Virtual Biotech program in partnership with the Parkinson’s Foundation, the trial now enters a three-month treatment phase, with top-line results anticipated in Q2 2026.
Syntara CEO Gary Phillips highlighted the logistical challenges overcome in completing recruitment and underscored the significance of the study in advancing understanding of both symptom relief and disease biology in iRBD.
Professor Simon Lewis of Macquarie University added that positive outcomes could provide immediate therapeutic hope for patients while offering critical insight into early-stage intervention for neurodegeneration.
At the time of reporting, Syntara's share price was $0.33.